SCHEMBL24028071

SCHEMBL24028071

COC(=O)c1nc(-c2c(F)cccc2F)c(OC)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.41
ABL1 P00519 1/20 0.41
SRC P12931 1/20 0.41
GRM4 Q14833 1/20 0.40
PDE4D Q08499 1/20 0.39
ALDH1A1 P00352 4/20 0.39
KMT2A Q03164 2/20 0.39
POLB P06746 1/20 0.39
NPC1 O15118 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RAB9A P51151 2/20 0.38
CYP1A2 P05177 1/20 0.38
HTR5A P47898 1/20 0.38
HSD17B10 Q99714 1/20 0.37
KRAS P01116 1/20 0.37
MAPT P10636 1/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30213038 1.00 KDM4E (0.41) KDM4EABL1SRCGRM4PDE4D
SCHEMBL30212881 0.89 ALDH1A1 (0.39) KDM4EABL1SRCGRM4ALDH1A1
SCHEMBL24028387 0.89 ALDH1A1 (0.39) KDM4EABL1SRCGRM4ALDH1A1
SCHEMBL24027906 0.82 ALDH1A1 (0.40) KDM4EALDH1A1KMT2ANPC1SMN1; SMN2
SCHEMBL319079 0.79 CFTR (0.49) KDM4EALDH1A1SMN1; SMN2
SCHEMBL24028074 0.77 RPS6KA2 (0.36) PDE4DL3MBTL1HTR5AKRAS
SCHEMBL30213035 0.77 RPS6KA2 (0.36) PDE4DL3MBTL1HTR5AKRAS
SCHEMBL24028041 0.76 RPS6KA2 (0.38) KDM4EGRM4KMT2APOLBNPSR1
SCHEMBL30212983 0.76 RPS6KA2 (0.38) KDM4EGRM4KMT2APOLBNPSR1
SCHEMBL24028392 0.75 ERN1 (0.37) ALDH1A1HTR5AKRASSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174507-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD. (IL) 2023-06-08 US disclosed
US-20230174507-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD. (IL) 2023-06-08 US disclosed
WO-2021229571-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD (IL) 2021-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174507-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, ADSS2, GLS2 KDM4E 1726/4885ABL1 3129/4885SRC 3483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.